Table 2.
Univariate and multivariate Cox Regression analysis.
| (A) | ||||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||||
| Variable | HR | 95% CI | p-value | HR | 95%CI | p-value |
| CTC count | 2.098 | 1.21-3.65 | 0.009 | 2.098 | 1.21-3.65 | 0.009 |
| Subtype | 0.765 | 0.42-1.38 | 0.373 | |||
| BRCA | 0.464 | 0.18-1.22 | 0.119 | |||
| BR grade | 0.677 | 0.35-1.32 | 0.251 | |||
| Palliative chemo | 0.949 | 0.57-1.60 | 0.844 | |||
| Palliative endo | 0.820 | 0.49-1.39 | 0.458 | |||
| Visceral metastases | 0.846 | 0.36-1.99 | 0.700 | |||
| WHO | 0.998 | 0.56-1.78 | 0.995 | |||
| Age | 1.022 | 0.99-1.05 | 0.145 | |||
| (B) | ||||||
| Univariate analysis | Multivariate analysis | |||||
| Variable | HR | 95% CI | p-value | HR | 95%CI | p-value |
| CTC count | 2.381 | 1.36-4.18 | 0.003 | 2.219 | 1.26-3.90 | 0.006 |
| Subtype | 0.974 | 0.54-1.74 | 0.928 | |||
| BRCA | 0.512 | 0.18-1.43 | 0.200 | |||
| BR grade | 0.568 | 0.29-1.11 | 0.100 | |||
| Palliative chemo | 2.139 | 1.22-3.75 | 0.008 | 1.958 | 1.12-3.44 | 0.019 |
| Palliative endo | 0.800 | 0.47-1.36 | 0.411 | |||
| Visceral metastases | 1.522 | 0.65-3.59 | 0.338 | |||
| WHO | 0.955 | 0.51-1.79 | 0.885 | |||
| Age | 1.026 | 1.00-1.06 | 0.060 | |||
Univariate and multivariate Cox regression analysis (n=65). (A) shows all variables in relation to PFS and (B) in relation to OS. CTC count was analyzed as dichotomized variable (<5 CTCs/≥5 CTCs) and age as continuous variable. For subtype patients were divided in ER+ versus TNBC and for BR (Bloom-Richardson) grade all patients were grade 2 or 3. Palliative chemotherapy was divided in 0-2 and 3-6 lines of chemotherapy for advanced breast cancer. Palliative endocrine therapies were divided in 0-1 and 2-6 lines of endocrine therapies for advanced breast cancer. WHO stands for WHO performance status and was divided in WHO 0 or WHO 1-2. HR, hazard ratio.
The significant values are shown in bold.